Verrica Pharmaceuticals Inc.
VRCA
$6.84
$0.6310.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -19.92% | -2,846.72% | -234.31% | 102.09% | 39.87% |
| Total Depreciation and Amortization | 2.11% | 3.26% | -7.54% | -4.33% | -17.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 82.49% | -30.24% | 58.79% | -19.61% | -63.71% |
| Change in Net Operating Assets | -200.60% | -74.69% | 168.35% | -153.10% | -12.10% |
| Cash from Operations | -99.59% | -147.40% | 196.43% | 20.77% | 21.08% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 99.69% | -803.77% | 4.12% | -2.42% | -984.76% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 97.86% | -- | -- | -- | -- |
| Cash from Financing | -100.88% | 442.39% | 4.12% | -2.42% | -110.29% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -202.57% | 58.74% | 140.15% | 15.15% | -171.60% |